BDX Files 8-K: Details Debt Maturities and Financials
Ticker: BDX · Form: 8-K · Filed: Feb 5, 2025 · CIK: 10795
Sentiment: neutral
Topics: debt, financials, disclosure
Related Tickers: BDX
TL;DR
BDX 8-K dropped: Lots of debt notes maturing soon, check the dates!
AI Summary
Becton, Dickinson & Co. (BDX) filed an 8-K on February 5, 2025, reporting on its financial condition and results of operations. The filing includes details on various debt instruments, such as notes due in 2025, 2026, 2031, 2032, and 2036, with varying interest rates.
Why It Matters
This filing provides investors with crucial information regarding Becton Dickinson's outstanding debt obligations and their respective maturity dates, impacting the company's financial structure and future borrowing capacity.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and debt instruments, not indicating any immediate operational or financial distress.
Key Numbers
- 2025 — Note Maturity Year (Short-term debt obligation)
- 2026 — Note Maturity Year (Medium-term debt obligation)
- 2031 — Note Maturity Year (Long-term debt obligation)
- 2032 — Note Maturity Year (Long-term debt obligation)
- 2036 — Note Maturity Year (Long-term debt obligation)
Key Players & Entities
- BECTON DICKINSON & CO (company) — Filer
- 0000010795 (company) — Central Index Key
- February 5, 2025 (date) — Report Date
- NJ (location) — State of Incorporation
- FRANKLIN LAKES (location) — Business Address City
- Notes 3.020 due May 24, 2025 (dollar_amount) — Debt Instrument
- Notes 1.208 due June 4, 2026 (dollar_amount) — Debt Instrument
- Notes 1.900 due December 15, 2026 (dollar_amount) — Debt Instrument
- Notes 3.519 due February 8, 2031 (dollar_amount) — Debt Instrument
- Notes 3.828 due June 7, 2032 (dollar_amount) — Debt Instrument
FAQ
What is the total principal amount of the notes maturing in 2025?
The filing lists 'Notes 3.020 due May 24, 2025' and 'Notes 0.034 due August 13, 2025', but the specific principal amounts are not detailed in this excerpt.
What are the interest rates for the notes maturing in 2026?
The filing indicates notes with interest rates of 1.208% due June 4, 2026, and 1.900% due December 15, 2026.
When do the notes with the highest stated interest rate mature?
The notes with the highest stated interest rate of 12.13% are due on February 12, 2036.
What is the company's primary business as indicated by its SIC code?
Becton Dickinson & Co.'s Standard Industrial Classification (SIC) code is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
What is the fiscal year end for Becton Dickinson & Co.?
The fiscal year end for Becton Dickinson & Co. is September 30 (0930).
Filing Stats: 782 words · 3 min read · ~3 pages · Grade level 9.7 · Accepted 2025-02-05 16:32:29
Key Financial Figures
- $1.00 B — ch registered Common stock, par value $1.00 BDX New York Stock Exchange 1.900% Notes
Filing Documents
- bdx-20250205.htm (8-K) — 43KB
- ex99112312024.htm (EX-99.1) — 564KB
- bd_newsxbdbxdsxseparationp.htm (EX-99.2) — 38KB
- image.jpg (GRAPHIC) — 12KB
- image_0.jpg (GRAPHIC) — 135KB
- 0000010795-25-000019.txt ( ) — 1111KB
- bdx-20250205.xsd (EX-101.SCH) — 4KB
- bdx-20250205_def.xml (EX-101.DEF) — 20KB
- bdx-20250205_lab.xml (EX-101.LAB) — 36KB
- bdx-20250205_pre.xml (EX-101.PRE) — 20KB
- bdx-20250205_htm.xml (XML) — 9KB
02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 5, 2025, Becton, Dickinson and Company ("BD") issued a press release announcing its financial results for its first fiscal quarter ending December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report. The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles ("non-GAAP measures"). Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release furnished as Exhibit 99.1.
01 REGULATION FD DISCLOSURE
ITEM 7.01 REGULATION FD DISCLOSURE On February 5, 2025, BD issued a press release announcing its board of directors has unanimously authorized BD management to pursue a plan to separate its Biosciences and Diagnostic Solutions business from the rest of BD. BD expects to announce more specifics on the separation plans by the end of fiscal 2025 and intends to target completion of the transaction in fiscal 2026. The completion of any separation transaction will be contingent upon various conditions and approvals, including approval of BD's board of directors, receipt of requisite regulatory clearances and compliance with applicable U.S. Securities and Exchange Commission requirements. No assurance can be given regarding the form that a separation transaction may take or the specific terms or timing, or that a separation will in fact occur. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated into this Item 7.01 by reference. The information in this Item 7.01 shall neither be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
01 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. Exhibit 99.1 Press release dated February 5, 2025, which is furnished pursuant to Item 2.02. Exhibit 99.2 Press release dated February 5, 2025, which is furnished pursuant to Item 7.01. Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BECTON, DICKINSON AND COMPANY (Registrant) By: /s/ Stephanie M. Kelly Stephanie M. Kelly Chief Securities and Governance Counsel, Corporate Secretary Date: February 5, 2025